Sage Therapeutics
215 First Street
Cambridge
MA
02142
United States
Tel: 617-299-8380
Website: https://www.sagerx.com/
About Sage Therapeutics
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner.
Stock Symbol:
SAGE
372 articles about Sage Therapeutics
-
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
11/8/2022
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the third quarter ended September 30, 2022.
-
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
11/1/2022
Sage Therapeutics today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer.
-
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
10/25/2022
Sage Therapeutics, Inc. announced that it will host a live webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET to review third quarter 2022 financial results and discuss recent business updates.
-
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
10/17/2022
Sage Therapeutics, Inc. and Biogen Inc. presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression, at the 35th European College of Neuropsychopharmacology Congress, taking place October 15-18, 2022, in Vienna, Austria.
-
Sage Therapeutics and Biogen’s zuranolone met its primary and key secondary endpoints in the Phase III SKYLARK study of women with postpartum depression (PPD). -
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here. -
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
9/19/2022
Sage Therapeutics, Inc. and Biogen Inc. announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder and postpartum depression.
-
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
9/2/2022
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 3:40 p.m. ET in New York, NY.
-
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
8/2/2022
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, reported business highlights and financial results for the second quarter ended June 30, 2022.
-
Sage Therapeutics to Present at Upcoming August 2022 Investor Conferences
8/1/2022
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will present at the following upcoming investor conferences in August:
-
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
7/19/2022
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that it will host a live webcast on Tuesday, August 2, 2022 at 8:00 a.m. ET to announce second quarter 2022 financial results and discuss recent business updates.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago. -
Sage Therapeutics to Present at Upcoming June 2022 Investor Conferences
6/2/2022
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will present at the following upcoming investor conferences in June.
-
Sage Therapeutics and partner Biogen shared news that their phase III Skylark study has yielded promising results for women suffering from severe postpartum depression (PPD). -
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
6/1/2022
Sage Therapeutics, Inc. and Biogen Inc. announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being evaluated in women with postpartum depression, met its primary and all key secondary endpoints.
-
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
5/4/2022
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will give a presentation at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 8:00am PT in Las Vegas, Nev.
-
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
5/3/2022
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, reported business highlights and financial results for the first quarter ended March 31, 2022.
-
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
5/2/2022
Sage Therapeutics, Inc. and Biogen Inc. initiated a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for zuranolone in the treatment of major depressive disorder.
-
Speculations that Biogen might appeal the decision after reports of the company hiring several lobbyists, including Clyburn Consulting and Federal Street Strategies.
-
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
4/19/2022
Sage Therapeutics, Inc. announced that it will host a live webcast on Tuesday, May 3, 2022 at 8:00 a.m. ET to announce first quarter 2022 financial results and discuss recent business updates.